Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Eidos Therapeutics Inc.
Sponsor

Eidos Therapeutics Inc.

United States 1800 Owens Street Suite C1200, 94158-2584, United States

About the sponsor

Eidos Therapeutics Inc. focuses on clinical research in symptomatic transthyretin amyloid cardiomyopathy, with attention to disease control, cardiac function, and the safety and tolerability of acoramidis in people living with established ATTR-CM.

  • Symptomatic ATTR-CM
  • Cardiac amyloidosis
  • Cardiovascular disease management

The sponsor also supports longer-term clinical follow-up in newly diagnosed patients, reflecting continued interest in the management of progressive amyloid-related heart disease.

About Specializations

Eidos Therapeutics Inc. runs clinical trials in conditions such as Cardiac amyloidosis, Acquired ATTR amyloidosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Cardiac amyloidosis

Recruiting

Long‑Term Study of Acoramidis on Heart Function and Amyloid Burden in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR‑CM)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Eidos Therapeutics Inc.

Acquired ATTR amyloidosis

Recruiting

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Cardiac amyloidosis

Not recruiting

Study on the Safety of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy Who Completed a Previous Trial

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.